Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1

被引:25
作者
de Mendoza, C
Rodriguez, C
Eiros, JM
Colomina, J
Garcia, F
Leiva, P
Torre-Cisneros, J
Aguero, J
Pedreira, J
Viciana, I
Corral, A
del Romero, J
de Lejarazu, RO
Soriano, V
机构
[1] Hosp Carlos III, Infect Dis Serv, Madrid, Spain
[2] Ctr Sanitario Sandoval, Madrid, Spain
[3] Hosp Clin, Microbiol Serv, Valladolid, Spain
[4] Hosp Ribera, Microbiol Serv, Valencia, Spain
[5] Hosp San Cecilio, Microbiol Serv, Granada, Spain
[6] Univ Oviedo, Hosp Cent Asturias, Microbiol Serv, E-33080 Oviedo, Spain
[7] Hosp Reina Sofia, Dept Internal Med, Cordoba, Spain
[8] Hosp Marques Valdecilla, Microbiol Serv, Santander, Spain
[9] Hosp Juan Canalejo, Dept Internal Med, La Coruna, Spain
[10] Hosp Virgen Victoria, Microbiol Serv, Malaga, Spain
关键词
D O I
10.1086/431203
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Human immunodeficiency virus (HIV) treatment guidelines have evolved, shifting from more-aggressive to more-conservative approaches. The potential impact of these shifts on the transmission of drug-resistant virus is unknown. Methods. Drug-resistance genotypes were examined in all consecutive patients with recent HIV type 1 (HIV1) seroconversion (hereafter, "HIV-1 seroconverters") seen at 10 Spanish hospitals since 1997. During the same period, the proportion of patients with chronic HIV-1 infection having undetectable viremia was examined, to estimate the extent and effectiveness of antiretroviral therapy. Results. A total of 141 recent HIV-1 seroconverters were identified, 67.4% of whom were men who have sex with men. The rate of primary drug-resistance mutations, by year of infection, was 33.3% for 1997, 29.4% for 1998, 20% for 1999, 14.3% for 2000, 3.4% for 2001, 15.4% for 2002, and 10.9% for 2003. On the other hand, the proportion of 8388 persons with chronic HIV-1 carriage who had an undetectable virus load was 33.4% for 1997, 34.6% for 1998, 39.7% for 1999, 47.5% for 2000, 52.9% for 2001, 39.7% for 2002, and 58.1% for 2003. A significant inverse correlation between transmission of drug-resistant HIV-1 and undetectable virus load was found (r = -0.955, by Spearman's test; P = .001). The lowest rate of transmission of drug-resistant HIV-1 was seen in 2001, when relatively " aggressive" treatment guidelines were used. Transmission of drug- resistant HIV-1 increased in 2002, in parallel with a reduction in the number of patients with chronic HIV-1 carriage and undetectable virus load, reflecting the popularity of drug holidays or treatment interruptions. Conclusion. The rate of drug resistance in recent HIV-1 seroconverters inversely correlates with the proportion of chronically HIV-1-infected individuals who have undetectable virus loads in the same region, which indirectly reflects antiretroviral treatment rules at any given time.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 50 条
  • [41] Viral load and heterosexual transmission of human immunodeficiency virus type 1
    Quinn, TC
    Wawer, MJ
    Sewankambo, N
    Serwadda, D
    Li, CJ
    Wabwire-Mangen, F
    Meehan, MO
    Lutalo, T
    Gray, RH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (13) : 921 - 929
  • [42] Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study
    Schooley, RT
    Ruane, P
    Myers, RA
    Beall, G
    Lampiris, H
    Berger, D
    Chen, SS
    Miller, MD
    Isaacson, E
    Cheng, AK
    [J]. AIDS, 2002, 16 (09) : 1257 - 1263
  • [43] SORIANO V, 2000, AIDS REV, V2, P111
  • [44] Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults - A randomized equivalence trial
    Staszewski, S
    Keiser, P
    Montaner, J
    Raffi, F
    Gathe, J
    Brotas, V
    Hicks, C
    Hammer, SM
    Cooper, D
    Johnson, M
    Tortell, S
    Cutrell, A
    Thorborn, D
    Isaacs, R
    Hetherington, S
    Steel, H
    Spreen, W
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (09): : 1155 - 1163
  • [45] Enhanced risk of HIV sexual transmission during structured treatment interruption
    Teicher, E
    Casagrande, T
    Vittecoq, D
    [J]. SEXUALLY TRANSMITTED INFECTIONS, 2003, 79 (01) : 74 - 74
  • [46] WAWER MJ, 2003, 10 C RETR OPP INF BO, P71
  • [47] WENSING AMJ, 2003, ANTIVIR THER, V8, pS131
  • [48] Wensing Annemarie M. J., 2003, AIDS Reviews, V5, P140
  • [49] Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel
    Yeni, PG
    Hammer, SM
    Hirsch, MS
    Saag, MS
    Schechter, M
    Carpenter, CCJ
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Schooley, RT
    Thompson, MA
    Vella, S
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02): : 251 - 265
  • [50] Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
    Yerly, S
    Vora, S
    Rizzardi, P
    Chave, JP
    Vernazza, PL
    Flepp, M
    Telenti, A
    Battegay, M
    Veuthey, AL
    Bru, JP
    Rickenbach, M
    Hirschel, B
    Perrin, L
    [J]. AIDS, 2001, 15 (17) : 2287 - 2292